Retagliptin
Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes. In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370837440 under CC BY-SA 4.0; modifications have been made.